Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Elna Osso"'
Autor:
Catherine Hewison, Uzma Khan, Mathieu Bastard, Nathalie Lachenal, Sylvine Coutisson, Elna Osso, Saman Ahmed, Palwasha Khan, Molly F Franke, Michael L Rich, Francis Varaine, Nara Melikyan, Kwonjune J Seung, Malik Adenov, Sana Adnan, Narine Danielyan, Shirajul Islam, Aleeza Janmohamed, Hayk Karakozian, Maureen Kamene Kimenye, Ohanna Kirakosyan, Begimkul Kholikulov, Aga Krisnanda, Andargachew Kumsa, Garmaly Leblanc, Leonid Lecca, Mpiti Nkuebe, Shahid Mamsa, Shrivani Padayachee, Phone Thit, Carole D Mitnick, Helena Huerga
Publikováno v:
Clinical Infectious Diseases. 75:1006-1013
Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens containing bedaquiline and/or delamanid. Methods Multicentre (16 countries), pros
Autor:
Helena Huerga, Uzma Khan, Mathieu Bastard, Carole D Mitnick, Nathalie Lachenal, Palwasha Y Khan, Kwonjune J Seung, Nara Melikyan, Saman Ahmed, Michael L Rich, Francis Varaine, Elna Osso, Makhmujan Rashitov, Naseem Salahuddin, Gocha Salia, Epifanio Sánchez, Armine Serobyan, Muhammad Rafi Siddiqui, Dri Grium Tefera, Dmitry Vetushko, Lusine Yeghiazaryan, David Holtzman, Shirajul Islam, Andargachew Kumsa, Gamarly Jacques Leblanc, Olga Leonovich, Shahid Mamsa, Mohammad Manzur-ul-Alam, Zaw Myint, Shrivani Padayachee, Molly F Franke, Catherine Hewison
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(8)
Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet this combination is an important alternative for pat
Autor:
Saman Ahmed, Uzma Khan, G Leblanc, S Coutisson, N Lachenal, Cathy Hewison, Michael Rich, A Krisnanda, J Makaka, A Stambekova, S.S. Islam, Andargachew Kumsa, Helena Huerga, Carole D. Mitnick, Kwonjune J. Seung, Nara Melikyan, K Zarli, S Abebe, S Padayachee, S de Guadalupe, A Reshid, Francis Varaine, S Adnan, Hakob Atshemyan, Elna Osso, P Nair, S Aiylchiev, Y Sahabutdinova, Palwasha Khan, N Lomtadze, Perea Moreno, B Kholikulov
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 24(10)
SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support of UNITAID in April 2015, endTB (Expand New Drug markets for TB) facilitat
Autor:
Epifanio Sánchez Garavito, Geraint Davies, Gustavo E. Velásquez, Elna Osso, Meredith B Brooks, Leonid Lecca, Carole D. Mitnick, Julia Coit, Dante Elmo Vargas Vasquez, Dylan B. Tierney, Kwonjune J. Seung, Roger Calderon, Judith Jimenez, Karen Tintaya, Henry Pertinez, Charles A. Peloquin
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Rationale: We examined whether increased rifampin doses could shorten standard therapy for tuberculosis without increased toxicity. Objectives: To assess the differences across three daily oral doses of rifampin in change in elimination rate of Mycob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd0a680e4032f8075b72e27ed3d301e
Autor:
Geraint Davies, Karen Tintaya, Judith Jimenez, Epifanio Sánchez Garavito, Carole D. Mitnick, Meredith B Brooks, Leonid Lecca, Julia Coit, Gustavo E. Velásquez, Charles A. Peloquin, Roger Calderon, Elna Osso
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 199:1167-1168
Autor:
Meredith B. Milstein, Geraint Davies, Julia Coit, Leonid Lecca, Epifanio Sánchez Garavito, Dante Elmo Vargas Vasquez, Marcello Pagano, Carmen Contreras, Elna Osso, David Coleman, Kwonjune J. Seung, Roger Calderon, Charles A. Peloquin, Denis A. Mitchison, Carole D. Mitnick
Publikováno v:
BMC Infectious Diseases
BACKGROUND: Evidence has existed for decades that higher doses of rifampin may be more effective, but potentially more toxic, than standard doses used in tuberculosis treatment. Whether increased doses of rifampin could safely shorten treatment remai